Dr. Bo Jesper Hansen

Venture Partner

  • Medical Doctor, Urology
  • Joined Wellington in 2015
  • Co-Founder and Executive Chairman at Swedish Orphan Biovitrum
  • Board Member at Karolinska Development (Chairman), Laborie, GenSpera, Newron, Ablynx, Orphazyme, CMC


Dr. Bo Jasper Hansen served as Executive Chairman, and previously CEO, of Swedish Orphan Biovitrum (SOBI), a publicly-listed biotech company with a market cap of approx. €5bn focusing on rare diseases, which he helped build from scratch as an entrepreneur. Dr. Hansen has been and is currently serving on the boards of several European companies, both private and publicly listed, which are active in the fields of pharmaceuticals and medical technology.

These include Laborie and Karolinska Development (Chairman), Newron, CMC, Genspera, Azanta and Orphazyme as well as Gambro (acquired by Baxter), Zymenex (acquired by Chiesi), Hyperion (acquired by Horizon) and Ablynx (acquired by Sanofi). Dr. Hansen studied Medicine at the University of Copenhagen (Denmark).